Seeking Alpha

ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design...

ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design clinical trial for its lead developmental drug, Gencaro, in atrial fibrillation. Medtronic (MDT) will be collaborating on the initial, phase 2B portion of the proposed trial.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)